PL2417156T3 - Trójwartościowe, bispecyficzne przeciwciała - Google Patents
Trójwartościowe, bispecyficzne przeciwciałaInfo
- Publication number
- PL2417156T3 PL2417156T3 PL10712365T PL10712365T PL2417156T3 PL 2417156 T3 PL2417156 T3 PL 2417156T3 PL 10712365 T PL10712365 T PL 10712365T PL 10712365 T PL10712365 T PL 10712365T PL 2417156 T3 PL2417156 T3 PL 2417156T3
- Authority
- PL
- Poland
- Prior art keywords
- trivalent
- bispecific antibodies
- bispecific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09005108 | 2009-04-07 | ||
EP10712365.5A EP2417156B1 (en) | 2009-04-07 | 2010-04-01 | Trivalent, bispecific antibodies |
PCT/EP2010/002122 WO2010115589A1 (en) | 2009-04-07 | 2010-04-01 | Trivalent, bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2417156T3 true PL2417156T3 (pl) | 2015-07-31 |
Family
ID=40942481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10712365T PL2417156T3 (pl) | 2009-04-07 | 2010-04-01 | Trójwartościowe, bispecyficzne przeciwciała |
Country Status (21)
Country | Link |
---|---|
US (4) | US20100256340A1 (pl) |
EP (1) | EP2417156B1 (pl) |
JP (2) | JP5616428B2 (pl) |
KR (1) | KR101456326B1 (pl) |
CN (1) | CN102369214B (pl) |
AR (1) | AR076193A1 (pl) |
AU (1) | AU2010234031B2 (pl) |
BR (1) | BRPI1010297A2 (pl) |
CA (1) | CA2757931C (pl) |
CY (1) | CY1116376T1 (pl) |
DK (1) | DK2417156T3 (pl) |
ES (1) | ES2537100T3 (pl) |
HR (1) | HRP20150444T1 (pl) |
IL (1) | IL214884A (pl) |
MX (1) | MX2011010168A (pl) |
PL (1) | PL2417156T3 (pl) |
PT (1) | PT2417156E (pl) |
SG (1) | SG175077A1 (pl) |
SI (1) | SI2417156T1 (pl) |
TW (1) | TW201039850A (pl) |
WO (1) | WO2010115589A1 (pl) |
Families Citing this family (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
KR101463631B1 (ko) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | 항체의 혈중 동태를 제어하는 방법 |
RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
MX2011010166A (es) * | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
MX2013000676A (es) | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer. |
EP2848940A1 (en) | 2010-07-19 | 2015-03-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
EP2600898A1 (en) | 2010-08-05 | 2013-06-12 | F.Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
DK2644698T3 (en) | 2010-11-17 | 2018-01-22 | Chugai Pharmaceutical Co Ltd | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
RU2013140685A (ru) * | 2011-02-04 | 2015-03-10 | Дженентек, Инк. | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
IN2013MN01438A (pl) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
AU2012244816B2 (en) | 2011-04-20 | 2015-12-10 | Roche Glycart Ag | Method and constructs for the pH dependent passage of the blood-brain-barrier |
AR086924A1 (es) | 2011-06-15 | 2014-01-29 | Hoffmann La Roche | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion |
WO2012176779A1 (ja) | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | 抗erbB3抗体 |
MX354663B (es) | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i. |
LT2748201T (lt) * | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
RS57744B1 (sr) * | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli |
WO2013041462A1 (en) | 2011-09-23 | 2013-03-28 | Roche Glycart Ag | Bispecific anti-egfr/anti igf-1r antibodies |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
MX349003B (es) | 2011-12-19 | 2017-07-06 | Hoffmann La Roche | Metodo para la deteccion del asociado de union libre de un aglutinante multiespecifico. |
PT2794905T (pt) * | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
KR20140107295A (ko) | 2011-12-22 | 2014-09-04 | 에프. 호프만-라 로슈 아게 | 진핵 세포용 전장 항체 표시 시스템 및 그것의 용도 |
KR102184059B1 (ko) | 2011-12-22 | 2020-11-30 | 에프. 호프만-라 로슈 아게 | 발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도 |
SG11201403443WA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
CN106443016B (zh) | 2012-02-01 | 2019-08-13 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的结合搭档的方法 |
CN104379601B (zh) | 2012-02-03 | 2021-04-09 | 霍夫曼-拉罗奇有限公司 | 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途 |
CA2861124A1 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
JP6152120B2 (ja) | 2012-02-15 | 2017-06-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc受容体に基づくアフィニティークロマトグラフィー |
PE20142422A1 (es) | 2012-04-05 | 2015-01-21 | Hoffmann La Roche | Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos |
MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
CN104411718B (zh) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
BR112014030844A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo |
JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 共有結合している抗原−抗体結合体 |
CN104394886B (zh) | 2012-07-04 | 2017-05-24 | 弗·哈夫曼-拉罗切有限公司 | 抗茶碱抗体及使用方法 |
ES2627482T3 (es) | 2012-07-13 | 2017-07-28 | F. Hoffmann-La Roche Ag | Procedimiento para la detección de una proteína de unión multiespecífica |
BR112015003938A2 (pt) | 2012-09-14 | 2018-09-04 | Hoffmann La Roche | métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
EA201500502A1 (ru) | 2012-11-08 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
BR112015021921A2 (pt) * | 2013-03-15 | 2017-08-29 | Merck Patent Gmbh | Anticorpos biespecíficos tetravalente |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
SG10201810481UA (en) | 2013-04-29 | 2018-12-28 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
RU2019108429A (ru) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения |
PL2992012T3 (pl) | 2013-04-29 | 2019-12-31 | F. Hoffmann-La Roche Ag | Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania |
US20160115231A1 (en) | 2013-05-21 | 2016-04-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
WO2015025054A1 (en) | 2013-08-22 | 2015-02-26 | Medizinische Universität Wien | Dye-specific antibodies for prestained molecular weight markers and methods producing the same |
EP3050896B1 (en) | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
CN105612182B (zh) * | 2013-10-11 | 2019-12-10 | 豪夫迈·罗氏有限公司 | 多特异性结构域交换共有可变轻链抗体 |
SG10202007189VA (en) | 2013-11-21 | 2020-09-29 | Hoffmann La Roche | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
WO2015091656A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE |
AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
EP3089996B1 (en) | 2014-01-03 | 2021-07-28 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
MX2016008191A (es) | 2014-01-03 | 2017-11-16 | Hoffmann La Roche | Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente. |
JP6602304B2 (ja) | 2014-01-03 | 2019-11-06 | エフ.ホフマン−ラ ロシュ アーゲー | 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途 |
CN111057151B (zh) | 2014-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
AU2015237184B2 (en) | 2014-03-28 | 2020-11-26 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
JP6666262B2 (ja) | 2014-04-02 | 2020-03-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体の軽鎖誤対合を検出するための方法 |
KR102246800B1 (ko) | 2014-05-13 | 2021-04-30 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
MX2016015280A (es) | 2014-06-26 | 2017-03-03 | Hoffmann La Roche | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. |
TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
JP6876601B2 (ja) | 2014-07-10 | 2021-05-26 | アフィリス・アクチェンゲゼルシャフトAffiris Ag | ハンチントン病の予防および/または処置における使用のための物質および方法 |
KR102317315B1 (ko) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
JP2017532019A (ja) | 2014-09-03 | 2017-11-02 | バイオアトラ、エルエルシー | 同じ真核細胞産生宿主における条件的活性型生物学的タンパク質の発見及び作製 |
CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
CN107074966A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体 |
JP6707090B2 (ja) | 2014-11-06 | 2020-06-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合が変更されたFc領域変種および使用方法 |
ES2835823T3 (es) | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
MY184268A (en) | 2014-11-26 | 2021-03-30 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
US20170269092A1 (en) | 2014-12-02 | 2017-09-21 | Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
PL3227332T3 (pl) * | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
KR20170094787A (ko) | 2014-12-18 | 2017-08-21 | 에프. 호프만-라 로슈 아게 | Cdc 유발 항체를 측정하기 위한 검정 및 방법 |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
JP6996983B2 (ja) * | 2015-06-16 | 2022-02-21 | ジェネンテック, インコーポレイテッド | 抗cll-1抗体及び使用方法 |
PL3313877T3 (pl) | 2015-06-24 | 2020-11-02 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
WO2017055399A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
KR20180073561A (ko) | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
AU2016329120B2 (en) | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
MA43018B1 (fr) | 2015-10-02 | 2021-11-30 | Hoffmann La Roche | Anticorps anti-pd1 et procédés d'utilisation |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
KR20180069065A (ko) | 2015-10-29 | 2018-06-22 | 에프. 호프만-라 로슈 아게 | 항-변이체 fc-부위 항체 및 사용 방법 |
EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC MEDICINE INDUCING CELLULAR INJURY FOR USE IN THE TREATMENT OF CANCER |
AU2017238172A1 (en) | 2016-03-21 | 2018-09-13 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
SI3433280T1 (sl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | S proteazo aktivirane bispecifične molekule celic T |
WO2017165681A1 (en) | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
JP6675017B2 (ja) * | 2016-05-02 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | コントースボディ−単鎖標的結合物質 |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
MX2018015173A (es) | 2016-06-17 | 2019-07-04 | Genentech Inc | Purificacion de anticuerpos multiespecificos. |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
AU2017291262A1 (en) | 2016-06-30 | 2019-01-03 | F. Hoffmann-La Roche Ag | Improved adoptive T-cell therapy |
AU2017297603A1 (en) | 2016-07-14 | 2019-02-14 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP6976315B2 (ja) | 2016-09-19 | 2021-12-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 補体因子に基づくアフィニティークロマトグラフィー |
JP6785372B2 (ja) | 2016-09-30 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ |
JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
CR20190297A (es) | 2016-11-23 | 2019-11-01 | Bioverativ Therapeutics Inc | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
AU2017381656B2 (en) | 2016-12-21 | 2020-07-02 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
WO2018184966A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
TWI747215B (zh) | 2017-04-05 | 2021-11-21 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
SI3606954T1 (sl) | 2017-04-05 | 2022-10-28 | F. Hoffmann - La Roche Ag | Protitelesa proti LAG3 |
EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
BR112020005737A2 (pt) * | 2017-09-22 | 2020-11-17 | F. Hoffmann-La Roche Ag | anticorpo recombinante multivalente e uso do mesmo, kit e método para detectar um antígeno |
AU2018358904A1 (en) * | 2017-11-01 | 2020-04-16 | F. Hoffmann-La Roche Ag | TriFab-contorsbody |
TWI829658B (zh) * | 2017-11-01 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性2+1康特斯體(Contorsbody) |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US20200300852A1 (en) | 2017-11-29 | 2020-09-24 | Hoffmann-La Roche Inc. | Target interference suppressed anti-drug antibody assay |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
JP7436365B2 (ja) | 2017-12-29 | 2024-02-21 | エフ. ホフマン-ラ ロシュ アーゲー | 抗vegf抗体及び使用の方法 |
JP2021511793A (ja) | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Lag3に結合する抗原結合部位を含む二重特異性抗体 |
WO2019149715A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Stabilized immunoglobulin domains |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
WO2019191552A1 (en) | 2018-03-29 | 2019-10-03 | Genentech, Inc. | Modulating lactogenic activity in mammalian cells |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US10640576B2 (en) | 2018-04-10 | 2020-05-05 | Y-Biologics Inc. | Cell engaging binding molecules |
WO2019199916A1 (en) * | 2018-04-13 | 2019-10-17 | Eli Lilly And Company | Fab-based trispecific antibodies |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
WO2020006511A1 (en) | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Trispecific antagonists |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
US20210284717A1 (en) * | 2018-07-11 | 2021-09-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
EP3838289A4 (en) | 2018-07-25 | 2022-08-03 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-TIGIT ANTIBODIES AND USES THEREOF |
EP3608674A1 (en) | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
CN113227359A (zh) | 2018-08-24 | 2021-08-06 | 耶达研究及发展有限公司 | 调节m2巨噬细胞极化的方法及其在治疗中的用途 |
MA53822A (fr) | 2018-10-03 | 2021-08-11 | Xencor Inc | Protéines de fusion fc hétérodimères d'il -12 |
CR20210330A (es) | 2018-12-21 | 2021-07-20 | Hoffmann La Roche | ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325) |
EP3902560A1 (en) | 2018-12-28 | 2021-11-03 | F. Hoffmann-La Roche AG | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
JP7241888B2 (ja) | 2018-12-30 | 2023-03-17 | エフ. ホフマン-ラ ロシュ アーゲー | pH勾配SPRに基づく結合アッセイ |
GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
GB2598218A (en) | 2019-02-21 | 2022-02-23 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
JP2022521750A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス,インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
JP7412440B2 (ja) | 2019-03-29 | 2024-01-12 | エフ. ホフマン-ラ ロシュ アーゲー | アビド結合多重特異性抗体を作製する方法 |
CN113646622A (zh) | 2019-03-29 | 2021-11-12 | 豪夫迈·罗氏有限公司 | 用于多价分子的功能分析的基于spr的结合测定 |
WO2020229378A1 (en) | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
EP3986924A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
AU2020297940A1 (en) | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
CA3140287A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
EP3986928A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
MX2021015538A (es) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
KR20220016957A (ko) | 2019-06-26 | 2022-02-10 | 에프. 호프만-라 로슈 아게 | Sirt-1 유전자 녹아웃을 갖는 포유류 세포주 |
CN114340735A (zh) | 2019-06-28 | 2022-04-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
JP2022543551A (ja) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Gprc5dに結合する抗体 |
KR20220028035A (ko) | 2019-07-31 | 2022-03-08 | 에프. 호프만-라 로슈 아게 | Gprc5d에 결합하는 항체 |
TW202126698A (zh) | 2019-09-18 | 2021-07-16 | 美商建南德克公司 | 抗klk7抗體、抗klk5抗體、多重特異性抗klk5/klk7抗體、及使用方法 |
CN114641270A (zh) | 2019-11-15 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 防止水性蛋白质溶液中可见颗粒的形成 |
US20230340119A1 (en) * | 2019-12-05 | 2023-10-26 | Arbele Corp | Composition of triax antibodies and method of making and using thereof |
PE20221282A1 (es) | 2019-12-18 | 2022-09-05 | Hoffmann La Roche | Anticuerpos que se unen a hla-a2/mage-a4 |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
CR20220334A (es) | 2019-12-23 | 2022-08-26 | Genentech Inc | Anticuerpos específicos de apolipoproteína l1 y métodos de uso |
EP4085251A1 (en) | 2020-01-02 | 2022-11-09 | F. Hoffmann-La Roche AG | Method for determining the amount of a therapeutic antibody in the brain |
EP4084821A2 (en) | 2020-01-03 | 2022-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
JP2023510382A (ja) | 2020-01-15 | 2023-03-13 | エフ. ホフマン-ラ ロシュ アーゲー | 組換えタンパク質製造プロセスから不純物を減少させる方法 |
WO2021195464A2 (en) | 2020-03-26 | 2021-09-30 | Genentech, Inc. | Modified mammalian cells |
CN115843312A (zh) | 2020-04-24 | 2023-03-24 | 马伦戈治疗公司 | 结合至t细胞相关癌细胞的多功能性分子及其用途 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ. ホフマン-ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
JP2023525898A (ja) | 2020-05-19 | 2023-06-19 | エフ. ホフマン-ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
JP2023527918A (ja) | 2020-06-08 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗hbv抗体及び使用方法 |
MX2022015899A (es) | 2020-06-16 | 2023-01-24 | Hoffmann La Roche | Metodo para determinar antigeno libre de un anticuerpo en una muestra. |
CN115698084A (zh) | 2020-06-19 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
AU2021291005A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and FolR1 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
EP4172192A1 (en) | 2020-06-24 | 2023-05-03 | Genentech, Inc. | Apoptosis resistant cell lines |
CN116133689A (zh) | 2020-07-07 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂 |
AU2021308653A1 (en) | 2020-07-17 | 2023-02-16 | Genentech, Inc. | Anti-Notch2 antibodies and methods of use |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
KR20230074144A (ko) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | NKp30에 결합하는 항체 분자 및 이의 용도 |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
TW202227625A (zh) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | 宿主細胞蛋白質之CRISPR/Cas9多重剔除 |
EP4214244A1 (en) | 2020-09-21 | 2023-07-26 | Genentech, Inc. | Purification of multispecific antibodies |
MX2023003328A (es) | 2020-09-24 | 2023-03-27 | Hoffmann La Roche | Lineas de celulas de mamifero con desactivacion genica. |
TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg結合抗mertk抗體及其使用方法 |
KR20220082775A (ko) | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | 항-pd-1 항체 및 이의 용도 |
JP7326584B2 (ja) | 2020-12-17 | 2023-08-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗hla-g抗体及びその使用 |
JP2024501662A (ja) | 2020-12-22 | 2024-01-15 | エフ. ホフマン-ラ ロシュ アーゲー | Xbp1を標的とするオリゴヌクレオチド |
CA3203257A1 (en) | 2020-12-23 | 2022-06-30 | Li Li | Anti-b7-h3 antibody and uses thereof |
CN114716548A (zh) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
JP2024509695A (ja) | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | 多重特異性結合タンパク質分解プラットフォームおよび使用方法 |
CN116888473A (zh) | 2021-02-18 | 2023-10-13 | 豪夫迈·罗氏有限公司 | 用于解析复杂、多步骤抗体相互作用的方法 |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
JP2024512377A (ja) | 2021-03-12 | 2024-03-19 | ジェネンテック, インコーポレイテッド | 抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法 |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
WO2022214565A1 (en) | 2021-04-09 | 2022-10-13 | F. Hoffmann-La Roche Ag | Process for selecting cell clones expressing a heterologous polypeptide |
EP4326855A1 (en) | 2021-04-19 | 2024-02-28 | Genentech, Inc. | Modified mammalian cells |
KR20240010469A (ko) | 2021-05-21 | 2024-01-23 | 제넨테크, 인크. | 관심 재조합 생성물의 생성을 위한 변형된 세포 |
CN113278071B (zh) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
US20220389120A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
CN117500829A (zh) | 2021-06-18 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
KR20240032930A (ko) | 2021-07-13 | 2024-03-12 | 제넨테크, 인크. | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
KR20240040770A (ko) | 2021-08-03 | 2024-03-28 | 제니시티 리미티드 | 조작된 tcr 복합체 및 이의 사용 방법 |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
WO2023094282A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Quantification of low amounts of antibody sideproducts |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
WO2023129974A1 (en) | 2021-12-29 | 2023-07-06 | Bristol-Myers Squibb Company | Generation of landing pad cell lines |
TW202340251A (zh) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | 抗notch2抗體及結合物及其使用方法 |
WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150149A (en) | 1976-11-29 | 1979-04-17 | Professional Staff Association Of The Los Angeles County Harbor General Hospital | Method and means for the early detection and diagnosis of certain types of cancers |
US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
PT95809A (pt) | 1989-11-07 | 1991-09-13 | Bristol Myers Squibb Co | Processo para a preparacao de imunoglobulinas oligomericas, nomeadamente anticorpos monoclonais oligomericos |
JPH06500780A (ja) | 1990-08-31 | 1994-01-27 | ブリストル―マイアーズ スクイブ カンパニー | ホモ接合免疫グロブリン |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
ES2173873T5 (es) | 1992-10-28 | 2007-03-01 | Genentech, Inc. | Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer. |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
GB9504344D0 (en) | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
EP0894135B1 (en) * | 1996-04-04 | 2004-08-11 | Unilever Plc | Multivalent and multispecific antigen-binding protein |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
CA2297692A1 (en) | 1997-08-18 | 1999-02-25 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
AU2719099A (en) | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
DE69942148D1 (de) * | 1998-06-22 | 2010-04-29 | Immunomedics Inc | Gebrauch von bispezifischen antikörpern in diagnose und therapie |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
WO2000035956A1 (fr) | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
CN1232039A (zh) | 1999-04-02 | 1999-10-20 | 中国人民解放军海军总医院 | 一种基因工程双特异抗体及其应用 |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
PL358215A1 (pl) | 2000-03-24 | 2004-08-09 | Micromet Ag | Polipeptydy wielofunkcyjne zawierające miejsca wiążące się z epitopem kompleksu receptorowego NKG2D |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
DE10021678A1 (de) | 2000-05-05 | 2002-04-18 | Stefan Duebel | Antikörperkonstrukte mit variablen Regionen |
WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
RU2430927C2 (ru) | 2000-10-20 | 2011-10-10 | Тугаи Сейяку Кабусики Кайся | Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US20050123476A1 (en) | 2001-09-05 | 2005-06-09 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And | Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
AU2002337885B1 (en) | 2001-10-16 | 2003-04-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
WO2003093318A1 (en) | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
US6658672B2 (en) | 2002-05-06 | 2003-12-09 | Elvis Hsieh | Hinge of toilet bowl seat and toilet bowl cover |
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
PT1517921E (pt) | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
BR0315123A (pt) * | 2002-10-10 | 2005-08-16 | Merck Patent Gmbh | Composições farmacêuticas direcionadas a receptores erb-b1 |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
NZ603037A (en) | 2003-01-22 | 2014-05-30 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
MXPA05008521A (es) * | 2003-02-13 | 2005-10-20 | Pharmacia Corp | Anticuerpos a c-met para el tratamiento de canceres. |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
KR20120104408A (ko) | 2003-05-30 | 2012-09-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
EP1639009B1 (en) | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
WO2005004809A2 (en) | 2003-07-01 | 2005-01-20 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
AU2004261229A1 (en) | 2003-07-29 | 2005-02-10 | Eisai, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
JP2007503206A (ja) | 2003-08-22 | 2007-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法 |
AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
US20050064509A1 (en) | 2003-09-23 | 2005-03-24 | The Regents Of The University Of California | Use of templated self assembly to create novel multifunctional species |
CN1326881C (zh) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体,其制备方法及用途 |
ES2831379T3 (es) | 2003-10-09 | 2021-06-08 | Ambrx Inc | Derivados poliméricos para la modificación selectiva de proteínas |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
EP1718664A4 (en) | 2004-02-02 | 2008-08-13 | Ambrx Inc | MODIFIED HUMAN FOUR FIXED PROPELLANT (4HB) BEAM POLYPEPTIDES, AND USE THEREOF |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
NZ580115A (en) * | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
DK1871805T3 (da) | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf |
CN101163501A (zh) * | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
JP2008531049A (ja) | 2005-02-28 | 2008-08-14 | セントカー・インコーポレーテツド | ヘテロ二量体タンパク質結合組成物 |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
WO2006114700A2 (en) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
KR20080033480A (ko) | 2005-08-02 | 2008-04-16 | 바스프 에스이 | 프탈로니트릴의 연속 수소화에 의한 크실릴렌디아민의 제조방법 |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
KR101460932B1 (ko) | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
ES2411505T3 (es) | 2005-12-15 | 2013-07-05 | Medimmune Limited | Combinación del antagonista de la angiopoyetina-2 y del antagonista de VEGF-A, y/o KDR, y/o Flt1 para el tratamiento del cáncer |
FR2894959B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteur rar-gamma |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
CA2638794A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
NZ591252A (en) | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
WO2007108013A2 (en) | 2006-03-22 | 2007-09-27 | National Institute Of Immunology | Novel bioconjugates as therapeutic agent and synthesis thereof |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
WO2008005828A2 (en) | 2006-06-30 | 2008-01-10 | Novo Nordisk A/S | PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS COMPRISING ANTIBODY MOLECULES SPECIFIC TO LAMININ-5 α3 CHAIN DOMAINS G1G2 AND USE THEREOF |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
CN101205255A (zh) | 2006-12-14 | 2008-06-25 | 上海中信国健药业有限公司 | 抗cd20四价抗体、其制备方法和应用 |
CA2671734A1 (en) | 2006-12-19 | 2008-06-26 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
MX2009008656A (es) * | 2007-02-16 | 2009-11-10 | Merrimack Pharmaceuticals Inc | Anticuerpos contra erbb3 y usos de los mismos. |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
CN101952312A (zh) * | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
US20110245409A1 (en) | 2007-08-15 | 2011-10-06 | Hood David K | Polyvinylamide Polymers Containing Polymerizable Functionalities |
ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
DE102007038753A1 (de) | 2007-08-16 | 2009-02-19 | Giesecke & Devrient Gmbh | Vorrichtung und Verfahren für die Kalibrierung eines Sensorsystems |
KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Igf―1r의 다중 에피토프에 결합하는 조성물 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
JP2009181819A (ja) | 2008-01-31 | 2009-08-13 | Hitachi High-Technologies Corp | 荷電粒子線装置 |
JP4438875B2 (ja) | 2008-02-27 | 2010-03-24 | 三菱自動車工業株式会社 | 車両の貯蔵燃料量推定装置 |
EP2132228B1 (en) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
KR20110047255A (ko) | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-egfr/항-igf-1r 항체 |
EA201100527A1 (ru) | 2008-09-26 | 2011-10-31 | Юсб Фарма С.А. | Биологические продукты |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
SG10201605250SA (en) | 2008-10-14 | 2016-08-30 | Genentech Inc | Immunoglobulin variants and uses thereof |
WO2010065882A1 (en) | 2008-12-04 | 2010-06-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
AU2010233993A1 (en) | 2009-04-07 | 2011-09-08 | Roche Glycart Ag | Bispecific anti-ErbB-1/anti-c-Met antibodies |
DE102009016373A1 (de) | 2009-04-07 | 2010-10-21 | V. KRÜTTEN MEDIZINISCHE EINMALGERÄTE GmbH | Verbindungsstück für den Sondenschlauch einer enteralen Ernährungssonde und Anordnung aus einer enteralen Ernährungssonde und einem enteralen Überleitsystem |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JP5758888B2 (ja) | 2009-07-06 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重特異性ジゴキシゲニン結合抗体 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
PT2483310E (pt) | 2009-09-29 | 2014-10-07 | Roche Glycart Ag | Anticorpos bi-específicos agonistas do receptor de morte |
EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
US10081684B2 (en) | 2011-06-28 | 2018-09-25 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
RS57744B1 (sr) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
US20130060011A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Fc-free antibodies comprising two fab fragments and methods of use |
PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
SG11201403365TA (en) | 2011-12-21 | 2014-07-30 | Hoffmann La Roche | Rapid method for cloning and expression of cognate antibody variable region gene segments |
AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
KR20150013188A (ko) | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 |
EP2867255B1 (en) | 2012-06-27 | 2017-07-19 | F. Hoffmann-La Roche AG | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
CN104411718B (zh) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
EP2872170A4 (en) | 2012-07-13 | 2016-06-22 | Zymeworks Inc | BISPECIFIC ASYMMETRIC HETÉRODIMÈRES COMPRISING ANTI-CD3 RECOMBINANT PRODUCTS |
BR112015003938A2 (pt) | 2012-09-14 | 2018-09-04 | Hoffmann La Roche | métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico |
US20150239991A1 (en) | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
BR112015021921A2 (pt) | 2013-03-15 | 2017-08-29 | Merck Patent Gmbh | Anticorpos biespecíficos tetravalente |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
RU2017116020A (ru) | 2014-10-08 | 2018-11-12 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия биспецифичными антителами, специфичными к fap и dr5, и химиотерапевтические агенты |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
-
2010
- 2010-04-01 EP EP10712365.5A patent/EP2417156B1/en active Active
- 2010-04-01 US US12/752,216 patent/US20100256340A1/en not_active Abandoned
- 2010-04-01 ES ES10712365.5T patent/ES2537100T3/es active Active
- 2010-04-01 PT PT107123655T patent/PT2417156E/pt unknown
- 2010-04-01 PL PL10712365T patent/PL2417156T3/pl unknown
- 2010-04-01 AU AU2010234031A patent/AU2010234031B2/en active Active
- 2010-04-01 CN CN201080014248.3A patent/CN102369214B/zh active Active
- 2010-04-01 JP JP2012503913A patent/JP5616428B2/ja active Active
- 2010-04-01 DK DK10712365T patent/DK2417156T3/en active
- 2010-04-01 KR KR1020117023666A patent/KR101456326B1/ko active IP Right Grant
- 2010-04-01 BR BRPI1010297A patent/BRPI1010297A2/pt not_active Application Discontinuation
- 2010-04-01 CA CA2757931A patent/CA2757931C/en active Active
- 2010-04-01 SI SI201030925T patent/SI2417156T1/sl unknown
- 2010-04-01 SG SG2011072600A patent/SG175077A1/en unknown
- 2010-04-01 WO PCT/EP2010/002122 patent/WO2010115589A1/en active Application Filing
- 2010-04-01 MX MX2011010168A patent/MX2011010168A/es active IP Right Grant
- 2010-04-05 AR ARP100101122A patent/AR076193A1/es unknown
- 2010-04-06 TW TW099110642A patent/TW201039850A/zh unknown
-
2011
- 2011-08-29 IL IL214884A patent/IL214884A/en active IP Right Grant
-
2012
- 2012-08-07 US US13/568,224 patent/US9890204B2/en active Active
-
2014
- 2014-06-04 JP JP2014115650A patent/JP2014193181A/ja active Pending
-
2015
- 2015-04-24 HR HRP20150444TT patent/HRP20150444T1/hr unknown
- 2015-05-07 CY CY20151100398T patent/CY1116376T1/el unknown
-
2017
- 2017-12-28 US US15/857,473 patent/US20180282399A1/en not_active Abandoned
-
2019
- 2019-05-15 US US16/413,469 patent/US20200062826A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL214884A0 (en) | Trivalent, bispecific antibodies | |
IL215062A0 (en) | Bispecific anti-erbb-3/anti-c-met antibodies | |
IL214885A0 (en) | Bispecific anti-erbb-1/anti-c-met antibodies | |
IL233563A0 (en) | Bispecific anti-her antibodies | |
HK1182625A1 (en) | Bispecific antibodies | |
ZA201005348B (en) | Humanized anti-c5ar antibodies | |
IL214996A0 (en) | Anti-bcma antibodies | |
GB0920127D0 (en) | Antibodies | |
GB0909906D0 (en) | Antibodies | |
SG10201401331TA (en) | Anti-siglec-15 antibody | |
IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
HK1168871A1 (zh) | 單克隆抗體 | |
EP2412808A4 (en) | BISPECIFIC ANTIBODY TYPE LH | |
GB0920324D0 (en) | Antibodies | |
HK1170745A1 (en) | Antibodies against il-17br il-17br | |
GB2473934B (en) | Anti-VEEV antibody | |
EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
EP2424892A4 (en) | DC-STAMP ANTIBODY | |
GB0908945D0 (en) | Antibodies | |
GB0804687D0 (en) | Humanized antibody | |
GB0804684D0 (en) | Humanized antibody | |
GB0804686D0 (en) | Humanized antibody | |
GB0911712D0 (en) | Antibody |